Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10255132 | 0.85 | MAPT (0.46) | MAPTKMT2AGAAALDH1A1ADRA2C | |
| SCHEMBL12173546 | 0.83 | MAPT (0.49) | MAPTKMT2AGAAALDH1A1KDM4E | |
| SCHEMBL1766217 | 0.83 | ENPP2 (0.38) | MAPTHTR3ASMN1; SMN2 | |
| SCHEMBL22159076 | 0.82 | MAPT (0.47) | MAPTKMT2AGAAALDH1A1ADRA2C | |
| SCHEMBL21414367 | 0.81 | MAPT (0.43) | MAPTKMT2AGAAALDH1A1ADRA2C | |
| SCHEMBL30893590 | 0.80 | CHRNB2 (0.58) | ALDH1A1KDM4EHTR3ALMNASIRT6 | |
| SCHEMBL1766208 | 0.80 | CHRNB2 (0.58) | ALDH1A1KDM4EHTR3ALMNASIRT6 | |
| SCHEMBL23707095 | 0.80 | MAPT (0.42) | MAPTKMT2AGAAALDH1A1ADRA2C | |
| SCHEMBL21414320 | 0.80 | HRH4 (0.44) | MAPTKMT2AGAAALDH1A1ADRA2C | |
| SCHEMBL10256822 | 0.80 | CHKA (0.48) | MAPTKMT2AGAAALDH1A1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515656-B1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8383638-B2 | Aminobenzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383638-B2 | Aminobenzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| WO-2011084371-A1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, MTNR1B | MAPT 574/4885KMT2A 1189/4885GAA 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.